Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer

Autor:	Yixiang ZHU, Zhijie WANG
Jazyk:	čínština
Rok vydání:	2022
Předmět:	lung neoplasms antibody drug conjugates (adcs) precision medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 468-476 (2022)
Druh dokumentu:	article
ISSN:	1009-3419 1999-6187
DOI:	10.3779/j.issn.1009-3419.2022.102.22
Popis:	Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/d54e7b7f0e834b6b97f843bf5702dc46 Zobrazit plný text záznamu View record in DOAJ